News | July 06, 2012

Treatment time for common breast cancer could be cut in half

July 6, 2012 — Accelerated whole breast irradiation after lumpectomy is an effective treatment for ductal carcinoma in situ (DCIS), a very common early stage and noninvasive form of breast cancer, meaning many more breast cancer patients could see their treatment times reduced by half, according to a study in the June issue of the International Journal of Radiation Oncology•Biology•Physics, the official scientific journal of the American Society for Radiation Oncology (ASTRO).

The widespread use of mammography beginning in the early 1980s has led to a dramatic increase in the number of DCIS instances detected, making this one of the most common forms of breast cancer. Multiple studies have proven that lumpectomy plus radiation significantly reduces the risk of recurrence in both noninvasive and invasive breast cancers and for DCIS. The current standard of treatment is lumpectomy followed by five to six weeks of whole breast radiation.

However, for invasive cancers, the use of an accelerated form of radiation that increases the strength of dose per treatment and uses fewer treatment sessions overall has been established as effective, providing patients with a shorter treatment time with similar positive results. The effectiveness of an accelerated treatment time has not been established for DCIS.

Researchers in the study followed 145 DCIS patients who were treated with lumpectomy and accelerated whole breast irradiation or lumpectomy with accelerated whole breast irradiation plus an additional daily boost. At five years post-treatment, only 4.1 percent of patients experienced a recurrence, which is comparable to the five to 10 percent recurrence rate demonstrated in randomized trials for patients receiving standard radiation.

“The results of our study suggest that DCIS patients can be safely treated with a shorter regimen of radiotherapy,” said Silvia Formenti, M.D., senior author of the study and a radiation oncologist at New York University School of Medicine. “This is good news for many breast cancer patients who would prefer to receive their treatments in a shorter period of time, but also want the peace of mind that they are receiving the most effective treatment available.”

For more information: www.astro.org


Related Content

News | Radiation Oncology

May 2, 2025 — GE HealthCare has announced an intended expansion of its radiation oncology portfolio as well as the ...

Time May 03, 2025
arrow
News | Mammography

April 29, 2025 — iCAD, a global provider of clinically proven AI-powered cancer detection solutions, has announced a ...

Time April 29, 2025
arrow
News | Mammography

April 24, 2025 — GE HealthCare will feature its latest advancements in diagnostic accuracy and patient-centered breast ...

Time April 24, 2025
arrow
News | Radiology Education

April 21, 2025 — On June 20, the American Society of Radiologic Technologists (ASRT) will award Life Member status to ...

Time April 21, 2025
arrow
News | Radiology Business

April 16, 2025 — According to a new report, the U.S. Radiotherapy Market is projected to reach $2.49 billion by 2030 ...

Time April 17, 2025
arrow
News | ASTRO

March 14, 2025 — Another pivotal milestone in the nation’s fight against cancer recently took place with the ...

Time March 17, 2025
arrow
News | Artificial Intelligence

March 10, 2025 — Lunit, a provider of AI-powered solutions for cancer diagnostics and therapeutics, has published a ...

Time March 10, 2025
arrow
News | Artificial Intelligence

Feb. 19, 2025 — SimonMed Imaging and HeartLung Technologies have signed a strategic partnership to offer HeartLung's AI ...

Time March 04, 2025
arrow
News | Ultrasound Imaging

Jan. 28, 2025 — GE HealthCare recently announced it has received 510(k) clearance from the United States Food and Drug ...

Time January 29, 2025
arrow
News | Breast Imaging

Jan. 8, 2025 — ScreenPoint Medical has acquiredf Biomediq A/S, a research-based company focused on the research ...

Time January 10, 2025
arrow
Subscribe Now